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INTRODUCTION
Surgery is the most important treatment strategy for breast 
cancer. Breast-conserving therapy (BCT), consisting of breast 
conserving surgery followed by breast radiation therapy, has 
been considered on par with mastectomy as a standard surgi-
cal treatment once it was proven that the approach was not 
inferior in terms of survival outcomes compared with total 
mastectomy [1,2]. However, some breast cancers have multi-
centric or multifocal lesions in the ipsilateral breast [3,4], and 
these unexpected lesions may persist after breast-conserving 
surgery and cause locoregional recurrences [5,6]. Accordingly, 
surgeons need accurate preoperative imaging along with care-
ful physical examinations to develop a precise surgical plan. 
Conventional preoperative imaging studies include mam-
mography and breast ultrasonography. Recently, breast mag-
netic resonance imaging (MRI) has also been used for preop-
erative breast imaging [7].
The clinical role of preoperative MRI in patients with early 
breast cancer is controversial. Some investigators insist that 
preoperative MRI offers highly sensitive imaging that can help 
discover satellite lesions that cannot be detected with other 
conventional imaging methods [8,9]. Others argue that the 
low specificity of MRI leads to additional imaging with mini-
mal benefit or an increase in the rates of unnecessary total 
mastectomy [10,11]. In particular, recent studies suggest that 
preoperative MRI is not associated with reducing positive 
margins in patients who receive BCT [12,13]. Furthermore, 
MRI imaging may lead clinicians to perform total mastect-
omies more frequently in patients with early breast cancer be-
cause of the detection of more subclinical satellite nodules that 
could be controlled by adjuvant radiation therapy [14,15]. For 
this reason, those investigators suggested that preoperative 
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Purpose: The purpose of the study was to evaluate the effect of 
preoperative magnetic resonance imaging (MRI) on survival out-
comes for breast cancer. Methods: A total of 954 patients who 
had T1–2 breast cancer and received breast-conserving therapy 
(BCT) between 2007 and 2010 were enrolled. We divided the pa-
tients according to whether they received preoperative MRI or 
not. Survival outcomes, including locoregional recurrence-free 
survival (LRRFS), recurrence-free survival (RFS), and overall sur-
vival (OS), were analyzed. Results: Preoperative MRI was per-
formed in 743 of 954 patients. Clinicopathological features were 
not significantly different between patients with and without pre-
operative MRI. In the univariate analyses, larger tumors were 
marginally associated with poor LRRFS compared to smaller 
tumors (hazard ratio [HR], 3.22; p=0.053). Tumor size, histologic 
grade, estrogen receptor (ER), progesterone receptor (PR), hor-
monal therapy, and adjuvant chemotherapy status were associ-
ated with RFS. Larger tumor size, higher histologic grade, lack of 
ER and PR expression, and no hormonal therapy were associat-
ed with decreased OS. Tumor size was associated with LRRFS in 
the multivariate analyses (HR, 4.19; p=0.048). However, preoper-
ative MRI was not significantly associated with LRRFS, RFS, or 
OS in either univariate or multivariate analyses. Conclusion: Pre-
operative MRI did not influence survival outcomes in T1–2 breast 
cancer patients who underwent BCT. Routine use of preoperative 
MRI in T1–2 breast cancer may not translate into longer RFS and 
OS.
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MRI should be abandoned in routine practice for patients 
with early breast cancer. Several guidelines, including those 
from the National Comprehensive Cancer Network and the 
Korea Breast Cancer Society, specify that preoperative MRI 
can be used for specific clinical situations such as neoadjuvant 
settings and locally advanced breast cancer [16,17].
To date, most studies regarding preoperative MRI have fo-
cused on the detection of additional cancerous lesions in the 
breast, and few studies have investigated clinical outcomes of 
preoperative breast MRI. We evaluated the effect of preoper-




We retrospectively reviewed the records of 1,025 patients 
between 2007 and 2010 who underwent definitive breast-
conserving surgery for T1–2 breast cancer. Patients with in-
flammatory breast cancer, phyllodes tumor, Paget’s disease, 
neoadjuvant chemotherapy, distant metastasis, or lack of radi-
ation therapy after breast conserving surgery were excluded. 
Ultimately, 954 patients were included in the analysis and di-
vided into two groups according to whether they received 
preoperative MRI or not. To compare the clinicopathologic 
features between the two groups, the following variables were 
analyzed: age, tumor size, nodal status, subtype, grade, estro-
gen receptor (ER) and progesterone receptor (PR) status, che-
motherapy and radiation therapy status, and locoregional or 
systemic recurrence events. Approval for the study was grant-
ed by the Institutional Review Board of Yonsei University 
Hospital (number: 2015-0017).
Preoperative imaging technique
Preoperative MRI was performed with one of two types of a 
3.0-T MR system (Intera Achieva, Philips Healthcare/Ad-
vanced Technology Laboratories, Bothell, USA; MAGNETOM 
Trio a Tim System, Siemens Healthcare, Erlangen, Germany) 
with dedicated, bilateral breast coils. The MRI protocol in-
cluded a 3D coronal T1-weighted turbo fast low-angle shot 
sequence, transverse T2-weighted turbo spin-echo imaging, 
and dynamic contrast-enhanced MRI.
Histopathology
Tumor stage was based on the American Joint Committee 
on Cancer Staging manual sixth edition [18]. Histological 
grade was assessed by the modified Bloom-Richardson classi-
fication. ER and PR expression in the primary breast cancer 
were evaluated from formalin-fixed, paraffin-embedded 
whole sections of surgically resected breast cancer specimens 
using immunohistochemistry. Primary antibodies against ER 
(Clone SP1; Neomarkers for Lab Vision, Fremont, USA) and 
PR (Clone PgR 636; DAKO, Glostrup, Denmark) were used. 
The cutoff value for ER and PR positivity was greater than 
10% staining by immunohistochemistry [19].
Treatment
Standard treatment for patients with breast cancer in our 
institution was described in a previous study [20]. In brief, 
along with breast surgery, sentinel lymph node biopsy or stan-
dard axillary lymph node dissection was performed in the 
BCT group. After definitive surgery, all patients received 
whole breast radiotherapy. Patients with hormone receptor‐
positive tumors received adjuvant endocrine therapy using se-
lective estrogen receptor modulators or aromatase inhibitors. 
Most human epidermal growth factor receptor 2 positive tu-
mors were not treated with adjuvant trastuzumab because the 
Korean National Health Insurance did not reimburse for 
trastuzumab before 2009.
Statistical analysis
We used Student t-test to compare mean values for continu-
ous variables and results are given as mean± standard devia-
tion. Pearson chi-square test and Fisher exact test were used 
for measuring statistical differences in categorical variables, 
and all statistical tests were two-sided. 
Five-year locoregional recurrence-free survival (LRRFS), 
recurrence-free survival (RFS), and overall survival (OS) rates 
were calculated. LRRFS was calculated from the date of sur-
gery to the date of locoregional recurrence. Locoregional or 
distant recurrence and death from any cause were considered 
RFS. The event of OS was death from any cause. The Kaplan-
Meier method was used to plot survival and the log-rank test 
was applied to compare survival between groups. The Cox-
proportional hazard model was used for both univariate and 
multivariate analyses. A p< 0.05 was considered to be statisti-
cally significant. All statistical analyses were performed with 
SPSS Statistics version 20 (IBM Corp., Armonk, USA).
RESULTS
Of 954 patients who underwent BCT, 743 (77.8%) received 
preoperative MRI and 211 (22.2%) did not. The median follow-
up time after surgery was 64.5 months (range, 1–100 months) 
for patients with preoperative MRI and 78.5 months (range, 
0–101 months) for patients without preoperative MRI. The 
mean age was 48.9± 9.06 years in the preoperative MRI group 
and 50.5 ± 10.21 years in the conventional imaging group.
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Clinicopathological characteristics of the two groups are 
summarized in Table 1. Patients younger than 50 years of age 
were more likely to undergo preoperative MRI than those 
older than 50 years of age (56.1% vs. 46.9%, p= 0.018). More 
patients with preoperative MRI received hormonal therapy 
than did those without preoperative MRI (77.5% vs. 70.6%, 
p= 0.034). Tumor size, nodal status, histologic type, grade, ER 
and PR status, and adjuvant chemotherapy were not signifi-
cantly different between groups.
The log-rank test showed no significant difference between 
patients with preoperative MRI and those without in terms of 
LRRFS (p= 0.938) (Figure 1), RFS (p= 0.507) (Figure 2), and 
OS (p= 0.655) (Figure 3). Univariate analyses for survival out-
comes are summarized in Table 2. The tumor size (p= 0.053) 
showed a marginal association with LRRFS. Tumor size 
(p < 0.001), histologic grade (p = 0.016), ER (p = 0.015), PR 
(p= 0.010), hormonal therapy (p= 0.006), and adjuvant che-










Age at diagnosis (yr)* 48.9±9.06 50.5±10.21 0.098
Age (yr) 0.018
   ≤50 417 (56.1)  99 (46.9)
   >50 326 (43.9) 112 (53.1)
T stage 0.244
   T1 596 (80.2) 154 (73.0)
   T2 147 (19.8)  57 (27.0)
Nodal status 0.547
   Node negative 126 (17.0)  48 (22.7)
   Node positive 617 (83.0) 163 (77.3)
Histologic type 0.190
   Ductal 648 (87.2) 191 (90.5)
   Other  95 (12.8)  20 (9.5)
Histologic grade (n=806) 0.200
   I, II 456 (71.9) 132 (76.7)
   III 178 (28.1)  40 (23.3)
ER 0.318
   Negative 243 (32.7)  78 (37.0)
   Positive 500 (67.3) 133 (63.0)
PR 0.374
   Negative 302 (40.6)  93 (44.1)
   Positive 441 (59.4) 118 (55.9)
Hormone therapy 0.034
   No 167 (22.5)  62 (29.4)
   Yes 576 (77.5) 149 (70.6)
Chemotherapy 0.722
   No 334 (45.0)  92 (43.6)
   Yes 409 (55.0) 119 (56.4)
MRI=magnetic resonance imaging; ER=estrogen receptor; PR=progesterone 
receptor.
*Mean±SD.
Figure 1. Locoregional recurrence-free survival (LRRFS) of patients with 
breast-conserving therapy according to preoperative magnetic reso-
nance imaging (MRI). The blue line means the LRRFS of patients with 
preoperative MRI. The green line means LRRFS of patients without pre-
operative MRI. There was no significant difference in terms of survival 
outcome (5 yr LRRFS of patients with preoperative MRI vs. patients 























motherapy (p= 0.031) were significantly associated with RFS. 
OS was significantly associated with tumor size (p= 0.019), 
Figure 2. Difference of recurrence-free survival (RFS) outcomes of pa-
tients with breast-conserving therapy according to preoperative mag-
netic resonance imaging (MRI). The blue line means the RFS of patients 
with preoperative MRI. The green line means RFS of patients without 
preoperative MRI. There was no significant difference in terms of surviv-
al outcome (5 yr RFS of patients with preoperative MRI vs. patients 
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histologic grade (p = 0.010), ER (p = 0.010), PR (p = 0.047), 
and hormonal therapy (p= 0.014). 
Multivariate analyses for survival outcomes are summarized 
in Table 3. Higher T-stage was associated with poor LRRFS, 
RFS, and OS (Table 3). Preoperative MRI was not associated 
with better LRRFS (HR, 0.81; 95% CI, 0.14–4.70), RFS (HR, 
0.75; 95% CI, 0.30–1.83), and OS (HR, 1.18; 95% CI, 0.27–
5.08).
DISCUSSION
The detection of additional cancerous lesions via preoper-
ative MRI is clinically valuable only if it improves outcomes 
such as tumor recurrence rate, re-excision rate, disease-free 
survival, and OS. Several studies have examined the accuracy 
of MRI, reporting a high sensitivity; however, other studies re-
port its high sensitivity does not improve clinical outcomes 
[10,21-23]. Berg et al. [10] reported a retrospective analysis 
that included 121 cancerous breasts in which combined mammo-
graphy, clinical examination, and MRI were more sensitive 
than any other individual test or combination of tests. Schnall 
et al. [21] also described a multicenter prospective study with 
Table 2. Univariate analyses for survival outcomes
Variable
LRRFS RFS OS
p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI
Age (<50 yr vs. ≥50 yr) 0.570 1.411 0.430–4.628 0.785 0.919 0.504–1.679 0.472 0.724 0.300–1.747
MRI (none vs. done) 0.938 1.055 0.270–4.124 0.508 0.775 0.364–1.650 0.655 0.791 0.283–2.213
Tumor size (T1 vs. T2) 0.053 3.223 0.983–10.564 0.000 3.358 1.844–6.115 0.019 2.821 1.188–6.695
Nodal status (negative vs. positive) 0.307 0.035 0.000–21.727 0.789 1.106 0.529–2.311 0.897 0.931 0.312–2.772
Histologic type (ductal vs. other) 0.481 1.317 0.612–2.836 0.321 1.228 0.819–1.841 0.810 0.914 0.441–1.896
Histologic grade (I, II vs. III) 0.231 1.495 0.775–2.886 0.016 1.499 1.079–2.082 0.010 1.915 1.168–3.140
ER (negative vs. positive) 0.822 0.869 0.254–2.968 0.015 0.475 0.261–0.864 0.010 0.312 0.129–0.754
PR (negative vs. positive) 0.721 0.806 0.246–2.642 0.010 0.445 0.242–0.821 0.047 0.410 0.170–0.989
Hormonal therapy (none vs. done) 0.100 0.369 0.112–1.209 0.006 0.426 0.232–0.781 0.014 0.343 0.145–0.807
Adjuvant chemotherapy (none vs. done) 0.957 0.968 0.295–3.172 0.031 2.082 1.069–4.055 0.314 1.594 0.643–3.949
LRRFS= locoregional recurrence-free survival; RFS=recurrence-free survival; OS=overall survival; HR=hazard ratio; CI=confidence interval; MRI=magnetic reso-
nance imaging; ER=estrogen receptor; PR=progesterone receptor. 
Table 3. Multivariate analysis for survival outcomes
Variable
LRRFS RFS OS
p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI
MRI (none vs. done) 0.818 0.814 0.141–4.704 0.528 0.075 0.307–1.832 0.818 1.187 0.277–5.087
Age (<50 yr vs. ≥50 yr) 0.093 4.197 0.789–22.338 0.307 1.477 0.699–3.122 0.299 2.032 0.533–7.744
T stage (T1 vs. T2) 0.048 5.012 1.014–24.783 0.001 3.639 1.643–8.063 0.049 4.358 1.005–18.890
Nodal status (negative vs. positive) 0.979 0.000001 - 0.470 0.694 0.258–1.869 0.294 0.322 0.039–2.671
ER (negative vs. positive) 0.648 1.519 0.253–9.134 0.085 0.440 0.173–1.119 0.726 0.747 0.146–3.815
Grade (I/II vs. III) 0.174 1.868 0.759–4.596 0.272 1.297 0.815–2.064 0.061 2.439 0.961–6.194
LRRFS= locoregional recurrence-free survival; RFS=recurrence-free survival; OS=overall survival; HR=hazard ratio; CI=confidence interval; MRI=magnetic reso-
nance imaging; ER=estrogen receptor.
Figure 3. Difference of overall survival (OS) outcomes of patients with 
breast-conserving therapy according to preoperative magnetic reso-
nance imaging (MRI). The blue line means the OS of patients with pre-
operative MRI. The green line means OS of patients without preopera-
tive MRI. There was no significant difference in terms of survival out-
come (5 yr OS of patients with preoperative MRI vs. patients without 
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426 patients with confirmed breast cancer in which preoper-
ative MRI detected 24.3% additional cancer foci with 72.8% ac-
curacy. Similarly, Van Goethem et al. [22] reviewed 67 patients 
with dense breasts and a malignant breast tumor intended for 
conservative surgery and concluded that MRI was more accu-
rate in assessing tumor extent and multifocality in patients 
with dense breasts. According to these results, the high sensi-
tivity of MRI should lead to better survival outcomes in the 
preoperative MRI group, even if the tumors detected were 
clinically insignificant. However, Hlawatsch et al. [23] exam-
ined 104 women with findings highly suggestive of malignan-
cy in the breast with mammography, sonography, and MRI 
before surgery and asserted that routine MRI was unneces-
sary, even though it is the most sensitive method for detection 
of small tumors, because of its meager clinical benefit. 
Two prospective randomized trials, the Comparative Effec-
tiveness of MRI in Breast Cancer (COMICE) and MR Mam-
mography of Nonpalpable Breast Tumors (MONET) trials 
[24,25], were performed to evaluate the effect of preoperative 
MRI on surgical outcomes. The COMICE trial reported no 
significant difference in re-operation rates between the study 
and control groups. The MONET trial reported a higher re-
excision rate in the preoperative MRI group. Collectively, 
these prospective trials and retrospective studies focused on 
sensitivity and short-term surgical outcomes of preoperative 
MRI, and they did not describe any survival outcomes.
There are a few retrospective studies that set endpoints of 
survival outcomes, and the results have been inconsistent. 
Fischer et al. [26] compared 121 patients with preoperative 
MRI and 225 patients without and reported a decreased inci-
dence of local recurrence 40 months after treatment in the 
MRI group. However, the cancer stage was less advanced in the 
MRI group and adjuvant treatment was not balanced between 
the groups. Another retrospective study reported that the use 
of breast MRI at the time of initial diagnosis was not associated 
with an improvement in outcomes after BCT even though 
clinicopathologic features of both patient groups were different 
[27]. Patients in the preoperative MRI group were younger and 
had smaller tumors. Recently, there was a study that matched 
study groups to overcome these limitations. Sung et al. [12] in-
vestigated the effect of preoperative MRI on surgical and long-
term outcomes in breast cancer by comparing patients with 
and without MRI, matching the groups for age, tumor stage, 
and tumor histologic features. The investigators concluded that 
the use of preoperative MRI was not associated with a statisti-
cally significant improvement in long-term outcomes.
In our study, we compared patients with or without MRI 
during preoperative evaluation who received BCT. By virtue 
of our single institute design and the large number of included 
patients, preoperative MRI findings were systematically and 
uniformly linked to the operative plan and outcomes. Fur-
thermore, because insurance assured preoperative MRI start-
ed in 2007, the latest data was collected over a short period 
that minimized adjuvant treatment bias. In the current study, 
clinicopathologic characteristics and adjuvant treatment sta-
tus between the preoperative MRI and control groups were 
not significantly different, with the exception of age and hor-
monal therapy status (Table 1). In agreement with previous 
studies of long-term outcomes [12], our results showed that 
preoperative MRI did not affect survival outcomes in T1–2 
breast cancer patients who received BCT. This result was sup-
ported by multivariate analyses in the current study. The rea-
son that younger patients were more common in the preoper-
ative MRI group was because younger patients are more likely 
to agree to MRI to evaluate the possibility of breast-conserv-
ing surgery before definitive surgery. 
There are some limitations to this study. Because of recent 
advances in screening and multimodal treatment, survival 
outcomes of early breast cancer are excellent. There were rela-
tively few events (total recurrence events, 43 of 954 [4.5%]; lo-
coregional recurrence events, 11 of 954 [1.2%]; and death 
events, 22 of 954 [2.3%]). Because MRI for preoperative imag-
ing was gradually introduced, the follow-up periods for both 
groups were not equivalent (median follow-up of MRI vs. 
control, 64.5 months vs. 78.5 months, respectively). Although 
the differences were minor, patient characteristics were not 
completely balanced. Patients older than 50 years of age and 
without hormone therapy were more prevalent in the non-
MRI group. However, the multivariate analyses that were ad-
justed for these potentially confounding factors indicated that 
preoperative MRI was not associated with changes in survival 
outcomes.
Preoperative breast MRI has become more common in Korea 
recently because the national insurance system covers 90% 
of the cost of MRI and the cost to patients is only about 
150,000 KRW in our institution. This subsidization allows 
easy access to preoperative MRI for patients and surgeons in 
Korea, even though controversy still exists regarding the use 
of preoperative MRI. In this setting, Korean doctors com-
monly choose MRI as a preoperative evaluation method. Ac-
cording to results of this study, however, preoperative MRI 
does not affect long-term survival outcomes. To confirm these 
results, a randomized, prospective clinical trial should be con-
ducted.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interests. 
428  Jaegyu Ryu, et al.
http://ejbc.kr https://doi.org/10.4048/jbc.2016.19.4.423
REFERENCES
1.  Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham 
L, et al. Eight-year results of a randomized clinical trial comparing total 
mastectomy and lumpectomy with or without irradiation in the treat-
ment of breast cancer. N Engl J Med 1989;320:822-8.
2.  Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena 
M, et al. Comparing radical mastectomy with quadrantectomy, axillary 
dissection, and radiotherapy in patients with small cancers of the breast. 
N Engl J Med 1981;305:6-11.
3.  Lagios MD. Multicentricity of breast carcinoma demonstrated by rou-
tine correlated serial subgross and radiographic examination. Cancer 
1977;40:1726-34.
4.  Douek M, Vaidya JS, Baum M, Taylor I. Magnetic-resonance imaging 
and breast cancer multicentricity. Lancet 1998;352:652-3.
5.  Egan RL. Multicentric breast carcinomas: clinical-radiographic-patho-
logic whole organ studies and 10-year survival. Cancer 1982;49:1123-
30.
6.  Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon 
KA. Does multicentric/multifocal breast cancer differ from unifocal 
breast cancer? An analysis of survival and contralateral breast cancer 
incidence. Breast Cancer Res Treat 2009;117:365-70.
7.  Kopans DB, Meyer JE, Sadowsky N. Breast imaging. N Engl J Med 
1984;310:960-7. 
8.  Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann 
E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic 
resonance imaging for surveillance of women at high familial risk for 
breast cancer. J Clin Oncol 2005;23:8469-76.
9.  Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. 
American Cancer Society guidelines for breast screening with MRI as 
an adjunct to mammography. CA Cancer J Clin 2007;57:75-89. 
10.  Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis 
RS, et al. Diagnostic accuracy of mammography, clinical examination, 
US, and MR imaging in preoperative assessment of breast cancer. Radi-
ology 2004;233:830-49.
11.  Barchie MF, Clive KS, Tyler JA, Sutcliffe JB, Kirkpatrick AD, Bell LM, et 
al. Standardized pretreatment breast MRI: accuracy and influence on 
mastectomy decisions. J Surg Oncol 2011;104:741-5.
12.  Sung JS, Li J, Da Costa G, Patil S, Van Zee KJ, Dershaw DD, et al. Preop-
erative breast MRI for early-stage breast cancer: effect on surgical and 
long-term outcomes. AJR Am J Roentgenol 2014;202:1376-82.
13.  Pilewskie M, Olcese C, Eaton A, Patil S, Morris E, Morrow M, et al. 
Perioperative breast MRI is not associated with lower locoregional re-
currence rates in DCIS patients treated with or without radiation. Ann 
Surg Oncol 2014;21:1552-60.
14.  Bleicher RJ, Ciocca RM, Egleston BL, Sesa L, Evers K, Sigurdson ER, et 
al. Association of routine pretreatment magnetic resonance imaging 
with time to surgery, mastectomy rate, and margin status. J Am Coll 
Surg 2009;209:180-7.
15.  Brennan ME, Houssami N, Lord S, Macaskill P, Irwig L, Dixon JM, et 
al. Magnetic resonance imaging screening of the contralateral breast in 
women with newly diagnosed breast cancer: systematic review and me-
ta-analysis of incremental cancer detection and impact on surgical 
management. J Clin Oncol 2009;27:5640-9. 
16.  Clinical practice guidelines in oncology (NCCN guidelines) breast 
cancer screening and diagnosis. 2013. National Comprehensive Cancer 
Network. http://www.nccn.org/professionals/physician_gls/f_guide-
lines.asp. Accessed July 13th. 2014.
17.  Breast cancer treatment guideline. 2015. Korean Breast Cancer Society. 
http://www.kbcs.or.kr/journal/file/d_5_05.pdf. Accessed July 13th. 2014.
18.  Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. 
AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. 
19.  Park HS, Park S, Kim JH, Lee JH, Choi SY, Park BW, et al. Clinicopatho-
logic features and outcomes of metaplastic breast carcinoma: compari-
son with invasive ductal carcinoma of the breast. Yonsei Med J 2010;51: 
864-9.
20.  Cho JH, Park JM, Park HS, Park S, Kim SI, Park BW. Oncologic safety 
of breast-conserving surgery compared to mastectomy in patients re-
ceiving neoadjuvant chemotherapy for locally advanced breast cancer. J 
Surg Oncol 2013;108:531-6. 
21.  Schnall MD, Blume J, Bluemke DA, Deangelis GA, Debruhl N, Harms S, 
et al. MRI detection of distinct incidental cancer in women with prima-
ry breast cancer studied in IBMC 6883. J Surg Oncol 2005;92:32-8.
22.  Van Goethem M, Schelfout K, Dijckmans L, Van Der Auwera JC, Weyler 
J, Verslegers I, et al. MR mammography in the pre-operative staging of 
breast cancer in patients with dense breast tissue: comparison with 
mammography and ultrasound. Eur Radiol 2004;14:809-16.
23.  Hlawatsch A, Teifke A, Schmidt M, Thelen M. Preoperative assessment 
of breast cancer: sonography versus MR imaging. AJR Am J Roentgenol 
2002;179:1493-501.
24.  Turnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, et al. Com-
parative effectiveness of MRI in breast cancer (COMICE) trial: a ran-
domized controlled trial. Lancet 2010;375:563-71.
25.  Peters NH, van Esser S, van den Bosch MA, Storm RK, Plaisier PW, van 
Dalen T, et al. Preoperative MRI and surgical management in patients 
with nonpalpable breast cancer: the MONET-randomised controlled 
trial. Eur J Cancer 2011;47:879-86.
26.  Fischer U, Zachariae O, Baum F, von Heyden D, Funke M, Liersch T. 
The influence of preoperative MRI of the breasts on recurrence rate in 
patients with breast cancer. Eur Radiol 2004;14:1725-31.
27.  Solin LJ, Orel SG, Hwang WT, Harris EE, Schnall MD. Relationship of 
breast magnetic resonance imaging to outcome after breast-conserva-
tion treatment with radiation for women with early-stage invasive 
breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386-
91.
